MedinCell raises €28M in bank debt to match maturities with revenue ramp-up
What's the deal? MedinCellDealroom has a profile for this one. Try Dealroom →, a French drug-delivery biotech listed on Euronext Paris, has secured €28 million in non-dilutive loans from leading European commercial banks. The financing carries no covenant or equity-linked instruments and extends the company's debt maturity to mid-2031.
Why now? MedinCell is timing its debt profile to an expected revenue climb. That growth is tied to UZEDY, already on the market, and Olanzapine LAI, currently under regulatory review in the US with approval anticipated in the fourth quarter of 2026. Both products are partnered with TevaDealroom has a profile for this one. Try Dealroom →.
What's the endgame? Alongside the new loans, MedinCell will repay a €20 million tranche of its existing €40 million European Investment Bank credit facility, entered into in 2022, by the end of July 2026. The move pushes maturity out more than three years to align with future cash flows from milestones and royalties.
What they said: "This is a natural step in executing our 'Shift to Growth' strategy," said chief executive officer Christophe DouatDealroom has a profile for this one. Try Dealroom →. He added that the company is "aligning our financial structure with our expected revenue growth."
The signal: Non-dilutive bank debt lets MedinCell shore up its cash position without issuing new shares, a notable choice for a biotech betting on near-term commercial revenue rather than equity markets to fund its pipeline.
Read more: finanznachrichten.de
